Description: J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
Home Page: www.jbpharma.com
Cnergy IT Park
Mumbai,
400025
India
Phone:
91 22 2439 5200
Officers
Name | Title |
---|---|
Mr. Nikhil Ashokkumar Chopra | CEO & Whole-Time Director |
Suresh Amin | Assistant Vice President ? Human Resource |
Mr. Narayan Saraf | Chief Financial Officer |
Mr. Kunal Khanna | President of Operations |
Mr. Bhagwat Singh Deora | Vice President of Finance & Accounts |
Mr. Suresh Bhise | Vice President of Information & Technology |
Mr. Sridhar Bharadwaj | Vice President of HR & Administration |
Mr. Himanshu Ranvah | Vice President of Legal |
Mr. Pradeep Kumar Singh | President of Global Business |
Mr. Parmeshwar B. Bang | Executive Vice President of Operations of Daman |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 21.692 |
---|---|
Trailing PE: | 45.8765 |
Price-to-Book MRQ: | 8.5398 |
Price-to-Sales TTM: | 7.3734 |
IPO Date: | |
Fiscal Year End: | March |
Full Time Employees: | 5311 |